ECSP10010496A - Derivado heterociclico fusionado y su uso - Google Patents

Derivado heterociclico fusionado y su uso

Info

Publication number
ECSP10010496A
ECSP10010496A EC2010010496A ECSP10010496A ECSP10010496A EC SP10010496 A ECSP10010496 A EC SP10010496A EC 2010010496 A EC2010010496 A EC 2010010496A EC SP10010496 A ECSP10010496 A EC SP10010496A EC SP10010496 A ECSP10010496 A EC SP10010496A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
ring
fusioned
heterociclic
derivative
Prior art date
Application number
EC2010010496A
Other languages
English (en)
Inventor
Nobuhiro Fujii
Yuya Oguro
Satoshi Sasaki
Shigeru Kondo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP10010496A publication Critical patent/ECSP10010496A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención proporciona un compuesto que tiene una actividad inhibidora de Smo superior y baja toxicidad, que es suficientemente satisfactoria como producto farmacéutico. La presente invención proporciona un compuesto representado por la fórmula en donde anillo A es anillo de 5 a 7 miembros que esta opcionalmente sustituido, donde los sustituyentes están unidos opcionalmente entre sí para formar un anillo; X es O, S o NR1 (R1 es un átomo de hidrógeno o un grupo hidrocarburo que esta opcionalmente sustituido); R2 es carbamoilo que esta opcionalmente sustituido; y R3 es hidroxi que esta opcionalmente sustituido, o una sal del mismo.
EC2010010496A 2008-02-26 2010-09-23 Derivado heterociclico fusionado y su uso ECSP10010496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008045134 2008-02-26
JP2008256755 2008-10-01

Publications (1)

Publication Number Publication Date
ECSP10010496A true ECSP10010496A (es) 2010-10-30

Family

ID=40905094

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010496A ECSP10010496A (es) 2008-02-26 2010-09-23 Derivado heterociclico fusionado y su uso

Country Status (28)

Country Link
US (2) US8399449B2 (es)
EP (1) EP2247588B1 (es)
JP (2) JP4719317B2 (es)
KR (1) KR101569949B1 (es)
CN (1) CN102015705B (es)
AR (1) AR070479A1 (es)
AU (1) AU2009217982B2 (es)
BR (1) BRPI0908417B1 (es)
CA (1) CA2716773C (es)
CL (1) CL2009000429A1 (es)
CO (1) CO6321277A2 (es)
CR (1) CR11661A (es)
DO (1) DOP2010000260A (es)
EA (1) EA020144B1 (es)
EC (1) ECSP10010496A (es)
ES (1) ES2586252T3 (es)
GE (1) GEP20125664B (es)
HK (1) HK1150274A1 (es)
IL (1) IL207735A (es)
JO (1) JO3259B1 (es)
MA (1) MA32164B1 (es)
MX (1) MX2010009372A (es)
MY (1) MY150379A (es)
NZ (1) NZ587719A (es)
PE (1) PE20091556A1 (es)
TW (1) TWI480282B (es)
WO (1) WO2009107850A2 (es)
ZA (1) ZA201006063B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000429A1 (es) * 2008-02-26 2009-09-25 Takeda Pharmaceuticals Co Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
WO2011013752A1 (ja) * 2009-07-31 2011-02-03 塩野義製薬株式会社 縮合へテロ環誘導体を含有する医薬組成物
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
GEP20146075B (en) 2009-08-26 2014-04-10 Takeda Pharmaceuticals Co Fused heterocyclic ring derivative and usage thereof
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US8614208B2 (en) 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
EP2471791B1 (en) 2009-08-26 2014-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN104583194A (zh) 2012-05-11 2015-04-29 艾伯维公司 作为nampt抑制剂的哒嗪和吡啶衍生物
PT3077544T (pt) * 2013-12-03 2019-08-01 Celestra Life Science Llc Projeto baseado em fundamentos de uma terapia alvo para 0 cancro
WO2015140964A1 (ja) 2014-03-19 2015-09-24 株式会社 東芝 電池用電極材料、非水電解質電池及び電池パック
US20170015677A1 (en) * 2014-03-31 2017-01-19 Boston Biomedical, Inc. New tricyclic quinone derivative
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
US9962378B2 (en) * 2015-09-17 2018-05-08 Macau University Of Science And Technology ROS1 inhibitor and its use
EP3412667B1 (en) 2016-02-01 2021-11-03 Takeda Pharmaceutical Company Limited Cocrystal
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7091201B2 (ja) 2018-09-14 2022-06-27 株式会社東芝 活物質、電極、二次電池、電池パック、及び車両
RU2711968C1 (ru) * 2018-11-22 2020-01-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский национальный исследовательский политехнический университет" Анальгезирующее средство
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
CN113292477B (zh) * 2021-06-01 2023-06-02 四川大学 一种铱催化的碳氢活化反应合成异吲哚-1-酮类化合物的方法
CN113429422B (zh) * 2021-07-26 2022-05-10 中国人民解放军军事科学院军事医学研究院 一种噻吩并喹诺酮类化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012684B2 (ja) 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
FR2695126B1 (fr) * 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
JP3223289B2 (ja) 1992-10-22 2001-10-29 東洋アルミニウム株式会社 肉類調理器具および肉類調理方法
BR9910864A (pt) 1998-06-04 2002-02-05 Abbott Lab Compostos anti-inflamatórios para inibição de aderência celular
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
JP2006151810A (ja) * 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
EP1698335A4 (en) 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
US20070299102A1 (en) 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0614578A2 (pt) * 2005-08-16 2011-04-05 Irm Llc composto, composição farmacêutica como inibidores de proteìna cinases, bem como seu método e uso
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
WO2007085188A1 (en) * 2006-01-27 2007-08-02 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
KR20090006089A (ko) * 2006-04-14 2009-01-14 노파르티스 아게 헤지호그 경로 관련 질환의 치료에서의 바이아릴카르복스아미드의 용도
BRPI0808772A2 (pt) * 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
CL2009000429A1 (es) * 2008-02-26 2009-09-25 Takeda Pharmaceuticals Co Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.

Also Published As

Publication number Publication date
HK1150274A1 (zh) 2011-11-18
CO6321277A2 (es) 2011-09-20
DOP2010000260A (es) 2010-10-15
AU2009217982B2 (en) 2013-04-11
KR101569949B1 (ko) 2015-11-18
US8217176B2 (en) 2012-07-10
WO2009107850A3 (en) 2010-01-28
MY150379A (en) 2013-12-31
CL2009000429A1 (es) 2009-09-25
US8399449B2 (en) 2013-03-19
JP2011098978A (ja) 2011-05-19
EA020144B1 (ru) 2014-09-30
EP2247588A2 (en) 2010-11-10
EA201070994A1 (ru) 2011-04-29
AU2009217982A2 (en) 2010-10-07
BRPI0908417B1 (pt) 2022-01-11
GEP20125664B (en) 2012-10-10
CN102015705A (zh) 2011-04-13
CA2716773A1 (en) 2009-09-03
CN102015705B (zh) 2013-11-13
AR070479A1 (es) 2010-04-07
US20090227561A1 (en) 2009-09-10
KR20100137482A (ko) 2010-12-30
IL207735A (en) 2014-12-31
MA32164B1 (fr) 2011-03-01
ZA201006063B (en) 2011-10-26
CA2716773C (en) 2016-04-26
WO2009107850A2 (en) 2009-09-03
TWI480282B (zh) 2015-04-11
JO3259B1 (ar) 2018-09-16
IL207735A0 (en) 2010-12-30
JP5490030B2 (ja) 2014-05-14
EP2247588B1 (en) 2016-04-13
ES2586252T3 (es) 2016-10-13
TW200940548A (en) 2009-10-01
AU2009217982A1 (en) 2009-09-03
JP4719317B2 (ja) 2011-07-06
BRPI0908417A2 (pt) 2020-08-18
PE20091556A1 (es) 2009-11-03
JP2011513199A (ja) 2011-04-28
US20110003788A1 (en) 2011-01-06
NZ587719A (en) 2012-04-27
CR11661A (es) 2010-10-11
MX2010009372A (es) 2010-09-22

Similar Documents

Publication Publication Date Title
ECSP10010496A (es) Derivado heterociclico fusionado y su uso
UY31674A1 (es) Derivado heterocíclico fusionado y su uso
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
CR10088A (es) Compuestos de piperazina con accion herbicida
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
BR112012029647A2 (pt) novos derivados de pirimidinas
UY29613A1 (es) Compuestos quimicos vi
DE602006009789D1 (de) Acetylenderivate
ECSP10010602A (es) Compuestos de anillo fusionados y uso de los mismos
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
UY29804A1 (es) Quinolinas de alquilnitrilo
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos